Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

Free delivery worldwide

Available. Dispatched from the UK in 3 business days
When will my order arrive?


One of the most important developments in the field of cardiovascular medicine over the last two decades has been recognition of the key role played by arterial thrombosis in the pathogenesis of acute coronary syndromes, ischemic complications of percutane- ous coronary revascularization, and coronary and peripheral atherosclerosis. The phar- macologic armamentarium directed against vascular thrombosis has thus expanded substantially during that time, with development of new fibrinolytic agents, low-molecu- lar-weight heparins, direct thrombin inhibitors, antagonists to platelet activation, and the platelet glycoprotein lIb/IlIa inhibitors. Though clinical investigations of these com- pounds have been marked by failures as well as successes, there is little doubt that enhanced antithrombotic therapies have markedly improved the outcome of patients undergoing coronary revascularization or with acute coronary syndromes. Glycoprotein IIblIlIa receptor antagonists were introduced into clinical practice to overcome the limitations of approaches that inhibit only individual pathways of platelet activation.
Multiple mechanisms of platelet activation in response to different agonists converge on the platelet membrane glycoprotein IIblIlIa complex, the "final common pathway" of platelet aggregation. The clinical hemorrhagic syndrome caused by a rare inherited defect in this receptor (Glanzmann' s thrombasthenia), characterized by muco- cutaneous and postsurgical bleeding, but infrequent spontaneous organ (particularly central nervous system) bleeding, suggested that therapeutic inhibition of this receptor might be a potent, yet well-tolerated means of treating thrombotic disorders.
show more

Product details

  • Hardback | 476 pages
  • 182 x 254 x 32mm | 1,202.03g
  • Totowa, NJ, United States
  • English
  • Revised
  • 2nd ed. 2003
  • X, 476 p.
  • 1588291855
  • 9781588291851

Back cover copy

A. Michael Lincoff takes advantage of critically important new knowledge arising from recent clinical trials to update and expand his acclaimed Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. This substantially enhanced Second Edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes, on outcomes with chronic oral GPIIb/IIIa blockade following acute coronary syndromes, and on fibrinolytic therapy during acute myocardial infarctions. Additional enhancements include revised findings from the latest trials of GPIIb/IIIa inhibition during percutaneous coronary intervention, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. The book also explains the scientific basis of this therapy, evaluates its benefits and risks for patients, and summarizes detailed data from its various clinical trials.
Comprehensive and definitive, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, Second Edition offers physicians, cardiologists, emergency room doctors, and basic scientists a complete and authoritative review of the state-of-the-art in glycoprotein IIb/IIIa receptor inhibitor use today.
show more

Table of contents

Part I. Basic Principles

Thrombosis in Acute Coronary Syndromes and Coronary Interventions
Thaddeus R. Tolleson and Robert A. Harrington

Platelet Adhesion
Edward F. Plow

Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis
Patrick Andre and David R. Phillips

Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Abciximab
Tirofiban, and Eptifibatide, Barry S. Coller

Part II. Glycoprotein IIb/IIIa Blockade During Coronary Intervention

Abciximab During Percutaneous Coronary Intervention: EPIC, EPILOG, and EPISTENT Trials
A. Michael Lincoff

Eptifibatide in Coronary Intervention: The IMPACT and ESPRIT Trials
Jean-Pierre Dery, J. Conor O'Shea, and James E. Tcheng

Tirofiban in Interventional Cardiology: The RESTORE and TARGET Trials
Nicholas Valettas and Howard C. Herrmann

Overview of the Glycoprotein IIb/IIIa Interventional Trials
A. Michael Lincoff and Eric J. Topol

Part III. Glycoprotein IIb/IIIa Blockade for Acute Ischemic Syndromes

The Use of Abciximab in Therapy-Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot Trial and the CAPTURE Study
Marcel J. B. M. van den Brand and Maarten L. Simoons

David J. Moliterno

Platelet Glycoprotein IIb/IIIa Inhibitors and an Invasive Strategy
Christopher P. Cannon

Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction: Adjunctive Therapy to Percutaneous Coronary Interventions
Franz-Josef Neumann

Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: Adjunctive Therapy to Fibrinolysis
Sorin J. Brener

Part IV. Practical Issues and Future Applications

Economics of Glycoprotein IIb/IIIa Inhibition
Daniel B.Mark

Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents
Steven R. Steinhubl

Platelet Glycoprotein IIb/IIIa Antagonists: Their Interaction with Low-Molecular-Weight Heparins and Direct Thrombin Inhibitors
Amol S. Bapat, Naji Yazbek, and Neal S. Kleiman

Oral Agents
L. Kristin Newby

Platelet Glycoprotein IIb/IIIa Inhibitors: Effects Beyond the Platelet
Dean J. Kereiakes and Pascal J. Goldschmidt-Clermont

Cerebrovascular Interventions
Leslie Cho and Jay S. Yadav

Cerebrovascular Aspects of Glycoprotein IIb/IIIa Receptor Inhibitors
Cathy A. Sila

Evolution of Drug Development in Evidence-Based Medicine: Summary and the Future
David E. Kandzari, David F. Kong, and Robert M. Califf

show more

Review quote

"...provides the reader with extensive and profound information about this new class, based on data from completed and ongoing trials...can be recommended not only to cardiologists but to all clinicians and researchers interested in this field."

-Intensive Care Medicine
show more